Get the Stockscreener App
0.4635
5.86%
0.0339
Hcw Biologics Inc stock is traded at $0.4635, with a volume of 1.38M.
It is up +5.86% in the last 24 hours and up +10.92% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$0.4296
Open:
$0.4003
24h Volume:
1.38M
Relative Volume:
0.10
Market Cap:
$19.13M
Revenue:
$3.50M
Net Income/Loss:
$-37.33M
P/E Ratio:
-0.4635
EPS:
-1
Net Cash Flow:
$-19.15M
1W Performance:
+63.47%
1M Performance:
+10.92%
6M Performance:
-24.08%
1Y Performance:
-60.11%
1-Day Range:
$0.4002
$0.5091
1-Week Range:
$0.3804
$1.03
52-Week Range:
$0.2103
$2.52
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.4601 | 19.13M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.13 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.85 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.66 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hcw Biologics Inc Stock (HCWB) Latest News
Trading Day Review: HCW Biologics Inc (HCWB) Loses Momentum, Closing at 0.43 - The Dwinnex
The Business Case For Buying HCW Biologics Inc (NASDAQ: HCWB) Stock Now - Stocks Register
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
HCW Biologics: Buy Rating Affirmed Amid IND Clearance and Strategic Advancements - TipRanks
HCW-9302 gains IND clearance for first-in-human study in alopecia areata - BioWorld Online
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
HCW Biologics Inc Inc. (HCWB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Penny Stocks To ResearchFebruary 03rd - MarketBeat
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Pharma company granted FDA clearance for alopecia drug study - The Business Journals
Crude Oil Moves Higher; Owens & Minor Shares Plummet - Benzinga
FDA approves HCW Biologics trial for alopecia treatment - MSN
What's Going On With HCW Biologics Stock Monday? - Benzinga
A Potential Breakthrough in the Fight Against Alopecia Areata: What You Need to Know About HCW Biologics Inc. - RagingBull
Stock market news: MDJM surged by 74.54% while Tonix Pharmaceuticals Holding plunged by 49.31% during mid day trading - Business Upturn
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January - Benzinga
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results - Benzinga
HCW Biologics Advances with FDA Clearance for Trial - TipRanks
Stock market today: Tonix Pharmaceuticals Holding declined by 49.01% whereas HCW Biologics jumped by 176.78% in early trading - Business Upturn
HCW Biologics Says FDA Approves Trial of HCW9302 to Treat Alopecia Areata; Shares Rise Pre-Bell - Marketscreener.com
HCW Biologics Granted FDA Clearance to Evaluate One of the - GlobeNewswire
HCW Biologics Granted FDA Clearance to Evaluate One of the Company?s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial - Marketscreener.com
HCWB stock touches 52-week low at $0.25 amid market challenges - Investing.com Australia
HCW Biologics (NASDAQ:HCWB) Shares Down 20% – Here’s Why - Defense World
HCWB stock touches 52-week low at $0.25 amid market challenges By Investing.com - Investing.com South Africa
HCW Biologics Insiders Placed Bullish Bets Worth US$2.50m - Yahoo Finance
HCW Biologics (HCWB) Stock Price, News & Analysis - MarketBeat
HCW Biologics’ Founder and CEO to Address Opportunities and - GlobeNewswire
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 - The Manila Times
HCW Biologics CEO to Share Breakthrough Immunotherapy Insights at 2025 GenScript Forum - StockTitan
HCW Biologics : January 2025. - Marketscreener.com
HCW Biologics (NASDAQ:HCWB) Stock Price Up 1.2% – Here’s What Happened - Defense World
HCW Announces Written Notice From NASDAQ - MENAFN.COM
HCW Biologics Shares Fall Amid Delisting Notice From Nasdaq - Marketscreener.com
HCW Announces Written Notice from NASDAQ - Baystreet.ca
HCW Biologics Inc. Received NASDAQ Staff Determination Letter - GlobeNewswire
HCW Biologics Faces Nasdaq Delisting Threat After Market Value Falls Below $50M Requirement - StockTitan
HCW Biologics issues 2.55 million shares to Armistice Capital By Investing.com - Investing.com Nigeria
HCW Biologics issues 2.55 million shares to Armistice Capital - Investing.com India
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
HCW Biologics takes aim at CD8+ in deal with WY Biotech - The Pharma Letter
HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement - MSN
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.13% - MSN
HCW Biologics : Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules Form 8 K - Marketscreener.com
HCW Biologics Expands with New Financial Agreements - TipRanks
HCW Biologics prices $6.9M registered direct offering at $1.03 per share - Yahoo Finance
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
HCWB stock touches 52-week high at $1.97 amid robust gains - Investing.com Australia
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - Yahoo Finance
HCW Biologics Secures $6.9M Above-Market Offering with Warrant Coverage | HCWB Stock News - StockTitan
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):